Literature DB >> 21628493

Heterogeneity maintenance in glioblastoma: a social network.

Rudy Bonavia1, Maria-del-Mar Inda, Webster K Cavenee, Frank B Furnari.   

Abstract

Glioblastoma multiforme (GBM), the most common intracranial tumor in adults, is characterized by extensive heterogeneity at the cellular and molecular levels. This insidious feature arises inevitably in almost all cancers and has great significance for the general outcome of the malignancy, because it confounds our understanding of the disease and also intrinsically contributes to the tumor's aggressiveness and poses an obstacle to the design of effective therapies. The classic view that heterogeneity arises as the result of a tumor's "genetic chaos" and the more contemporary cancer stem cell (CSC) hypothesis tend to identify a single cell population as the therapeutic target: the prevailing clone over time in the first case and the CSC in the latter. However, there is growing evidence that the different tumor cell populations may not be simple bystanders. Rather, they can establish a complex network of interactions between each other and with the tumor microenvironment that eventually strengthens tumor growth and increases chances to escape therapy. These differing but complementary ideas about the origin and maintenance of tumor heterogeneity and its importance in GBM are reviewed here.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628493      PMCID: PMC3117065          DOI: 10.1158/0008-5472.CAN-11-0153

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  A perivascular niche for brain tumor stem cells.

Authors:  Christopher Calabrese; Helen Poppleton; Mehmet Kocak; Twala L Hogg; Christine Fuller; Blair Hamner; Eun Young Oh; M Waleed Gaber; David Finklestein; Meredith Allen; Adrian Frank; Ildar T Bayazitov; Stanislav S Zakharenko; Amar Gajjar; Andrew Davidoff; Richard J Gilbertson
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake.

Authors:  Laxminarayana R Devireddy; Claude Gazin; Xiaochun Zhu; Michael R Green
Journal:  Cell       Date:  2005-12-29       Impact factor: 41.582

3.  Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency.

Authors:  Mika Suzuki; Evangeline Sari Mose; Valerie Montel; David Tarin
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

4.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

5.  Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells.

Authors:  V Jung; B F Romeike; W Henn; W Feiden; J R Moringlane; K D Zang; S Urbschat
Journal:  J Neuropathol Exp Neurol       Date:  1999-09       Impact factor: 3.685

6.  Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study.

Authors:  K Nabeshima; Y Shimao; S Sato; H Kataoka; T Moriyama; H Kawano; S Wakisaka; M Koono
Journal:  Histopathology       Date:  1997-11       Impact factor: 5.087

7.  Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.

Authors:  Ryo Nishikawa; Tatsuya Sugiyama; Yoshitaka Narita; Frank Furnari; Webster K Cavenee; Masao Matsutani
Journal:  Brain Tumor Pathol       Date:  2004       Impact factor: 3.298

8.  Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas.

Authors:  K Harada; T Nishizaki; S Ozaki; H Kubota; H Ito; K Sasaki
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

9.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

10.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.

Authors:  Gentao Liu; Xiangpeng Yuan; Zhaohui Zeng; Patrizia Tunici; Hiushan Ng; Iman R Abdulkadir; Lizhi Lu; Dwain Irvin; Keith L Black; John S Yu
Journal:  Mol Cancer       Date:  2006-12-02       Impact factor: 27.401

View more
  209 in total

1.  Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.

Authors:  Yong Tang; Adly Yacoub; Hossein A Hamed; Andrew Poklepovic; Gary Tye; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2012-05-01       Impact factor: 4.742

Review 2.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

3.  Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.

Authors:  Andrew S Gilder; Karra A Jones; Jingjing Hu; Lei Wang; Clark C Chen; Bob S Carter; Steven L Gonias
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

4.  Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model.

Authors:  Vivian Adamski; Christina Schmitt; Florian Ceynowa; Rainer Adelung; Ralph Lucius; Michael Synowitz; Kirsten Hattermann; Janka Held-Feindt
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-01       Impact factor: 4.553

Review 5.  The value of EGFRvIII as the target for glioma vaccines.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

6.  Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.

Authors:  Alice M Walsh; Gurpreet S Kapoor; Janine M Buonato; Lijoy K Mathew; Yingtao Bi; Ramana V Davuluri; Maria Martinez-Lage; M Celeste Simon; Donald M O'Rourke; Matthew J Lazzara
Journal:  Mol Cancer Res       Date:  2015-05-01       Impact factor: 5.852

7.  Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.

Authors:  Gao Guo; Ke Gong; Vineshkumar Thidil Puliyappadamba; Nishah Panchani; Edward Pan; Bipasha Mukherjee; Ziba Damanwalla; Sabrina Bharia; Kimmo J Hatanpaa; David E Gerber; Bruce E Mickey; Toral R Patel; Jann N Sarkaria; Dawen Zhao; Sandeep Burma; Amyn A Habib
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

8.  Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.

Authors:  Elisa Carra; Federica Barbieri; Daniela Marubbi; Alessandra Pattarozzi; Roberto E Favoni; Tullio Florio; Antonio Daga
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

9.  microRNA-based cancer cell reprogramming technology.

Authors:  Shimpei Nishikawa; Hideshi Ishii; Naotsugu Haraguchi; Yoshihiro Kano; Takahito Fukusumi; Katsuya Ohta; Miyuki Ozaki; Dyah Laksmi Dewi; Daisuke Sakai; Taroh Satoh; Hiroaki Nagano; Yuichiro Doki; Masaki Mori
Journal:  Exp Ther Med       Date:  2012-04-23       Impact factor: 2.447

10.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity.

Authors:  Noemi Andor; Trevor A Graham; Marnix Jansen; Li C Xia; C Athena Aktipis; Claudia Petritsch; Hanlee P Ji; Carlo C Maley
Journal:  Nat Med       Date:  2015-11-30       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.